Risk of Systemic Autoimmune Diseases with Antiarrhythmic Drugs in Arrhythmia Patients: A Retrospective Cohort Study

Title:Risk of Systemic Autoimmune Diseases with Antiarrhythmic Drugs in Arrhythmia Patients: A Retrospective Cohort Study

Volume: 23 Issue: 14

Author(s): Jiun-Jie Lin, Hung-Yi Chen*, Mei-Chen Lin and Chung-Y. Hsu

Affiliation:

• Institute of Pharmacy, China Medical University, Taichung, Taiwan
• Department of Pharmacy, China Medical University Hospital, Beikang Campus, Yunlin, Taiwan

Abstract:

Background: The risk factors for Systemic Autoimmune Disease (SAD)s with antiarrhythmic drugs (AAD)s in arrhythmia patients are still unclear.

Aims: This study discussed these risk factors for SADs with AADs in arrhythmia patients.

Methods: This study was a retrospective cohort design and analyzed this relationship in an Asian population. Patients without a prior diagnosis of SADs were identified from Taiwan's National Health Insurance Research Database from January 1^st , 2000, to December 31^st , 2013. Cox regression models estimated the hazard ratio (HR) with a 95% confidence interval (CI) of SAD.

Results: We estimated the data of participants aged ≧ 20 or ≦ 100 years old and free of SADs at baseline. AAD users (n = 138376) had a significantly increased risk of SADs over non-AAD users. There was a significantly higher risk of developing SADs in all age and sex categories. The patients who received AADs, the autoimmune disease with the significantly higher risk was Systemic Lupus Erythematous (SLE) (adjusted HR (aHR) 1.53, 95% CI, 1.04-2.26), Sjögren syndrome (SjS) (For adjusted HR (For aHR) For 2.06 For, 95% CI, 1.59-2.66) and Rheumatoid Arthritis (RA) (aHR, 1.57, 95% CI, 1.26-1.94).

Conclusion: We concluded that there were statistical associations between AADs and SADs, and the higher incidence was SLE, SjS and RA in arrhythmia patients.

Cite this article as:

Lin Jiun-Jie, Chen Hung-Yi*, Lin Mei-Chen and Hsu Chung-Y., Risk of Systemic Autoimmune Diseases with Antiarrhythmic Drugs in Arrhythmia Patients: A Retrospective Cohort Study, Endocrine, Metabolic & Immune Disorders - Drug Targets 2023; 23 (14) . https://dx.doi.org/10.2174/1871530323666230419085348